Oramed Pharma (ORMP)

$2.09 +0.01 (0.48%)
Market Cap 85.16M
Revenue (ttm) 0.00
Net Income (ttm) -19.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 36,346
Avg Vol 77,302
Day's Range N/A - N/A
Shares Out 40.85M
Stochastic %K 10%
Beta 1.60
Analysts Hold
Price Target $3.25

Company Profile

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is he...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 967 2633
Address:
1185 Avenue of the Americas, Third Floor, New York, United States
WallStWireAds
WallStWireAds Aug. 4 at 12:34 AM
$ORMP The Next $1B Radiotherapy Bet? Why Alpha Tau Medical May Be One Breakthrough Away https://thefinanceherald.com/the-next-1b-radiotherapy-bet-why-alpha-tau-medical-may-be-one-breakthrough-away/
0 · Reply
ZacksSCR
ZacksSCR Jul. 28 at 9:09 PM
With Substantial Liquidity, $ORMP Has Generated Gains & Income From Investment Portfolio https://buff.ly/21CyOnj
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 25 at 12:28 AM
$ORMP Great piece that accurately captures ORMP's current position. So if you want to refresh your understanding of ORMP or learn about ORMP for the first time, this is essential reading. https://beyondspx.com/article/oramed-pharmaceuticals-oral-delivery-ambitions-face-pivotal-juncture-amidst-strategic-diversification-nasdaq-ormp
0 · Reply
kshonstocks
kshonstocks Jul. 23 at 6:39 PM
$ORMP alert hits some volume coming in
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 23 at 3:49 PM
$ORMP Very bullish. Load up early PT $3.5
0 · Reply
amitzak
amitzak Jul. 18 at 4:50 PM
$ORMP I'm in because: 1. Healthy cash status 2. started also investing in real estate lately 3. the company announced a one-year extension, allowing it to repurchase up to $20 million in value of its common stock, with the program now expiring in June 2026. As of May 2025, Oramed had repurchased approximately $2.5 million worth of shares under this program. 4. the price is near long term support levels.
0 · Reply
positiveguy
positiveguy Jul. 2 at 9:28 PM
$ORMP Trust me do not buy this stock. it is run by incompetent people and liars. the Ceo knows zero about managing a business. He pumped his bullshit drug for 20 years and has nothing to show for it except all the money he pilfered from the company. Look at how much he pays himself and his 90 year old mother and you will throw up. Shocked the SEC has not investigated this scam.
4 · Reply
Newyork_
Newyork_ Jul. 2 at 6:08 PM
$ORMP how are they still going
0 · Reply
CallMeMyBeer
CallMeMyBeer Jun. 27 at 9:15 PM
$ORMP its been years since their phase 3 failure and still no signs of anything working.
0 · Reply
PSDL75
PSDL75 Jun. 20 at 11:17 AM
$ORMP Quick glance at their pipeline, spend and cash - they seem in a decent sport, but not sure what amount of potential they actually have. The oral drug delivery companies appear to not be going anywhere. Though they have a cash runway...but the concerning part is all the financial finagling.. just going to watch this one.
1 · Reply
Latest News on ORMP
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Apr 28, 2025, 9:00 AM EDT - 3 months ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

DRTS

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Apr 28, 2025, 9:00 AM EDT - 3 months ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

DRTS

Oramed Pharmaceuticals Issues Letter to Shareholders

Mar 4, 2025, 9:00 AM EST - 5 months ago

Oramed Pharmaceuticals Issues Letter to Shareholders

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

Feb 11, 2025, 9:15 AM EST - 6 months ago

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

Oct 7, 2024, 10:00 AM EDT - 10 months ago

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

SCLX

Oramed Letter to Shareholders

Jun 26, 2024, 9:05 AM EDT - 1 year ago

Oramed Letter to Shareholders

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

Jun 26, 2024, 9:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

Sep 21, 2023, 6:11 PM EDT - 2 years ago

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

Aug 2, 2023, 7:45 AM EDT - 2 years ago

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

Oramed to Present at the 83rd American Diabetes Association Conference

Jun 20, 2023, 7:55 AM EDT - 2 years ago

Oramed to Present at the 83rd American Diabetes Association Conference

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

May 18, 2023, 7:55 AM EDT - 2 years ago

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

May 15, 2023, 9:05 AM EDT - 2 years ago

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

Oramed Pharmaceuticals Issues Shareholder Update

Feb 9, 2023, 7:55 AM EST - 2 years ago

Oramed Pharmaceuticals Issues Shareholder Update

Oramed's oral insulin pill fails; stock is down 72%

Jan 12, 2023, 8:02 AM EST - 2 years ago

Oramed's oral insulin pill fails; stock is down 72%

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Jan 11, 2023, 8:00 PM EST - 2 years ago

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

Jan 4, 2023, 7:55 AM EST - 2 years ago

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

Oramed: NASH Biotech Play With Added Bonus

Dec 7, 2022, 3:49 AM EST - 2 years ago

Oramed: NASH Biotech Play With Added Bonus

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

Nov 29, 2022, 8:40 AM EST - 2 years ago

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea

Nov 18, 2022, 4:11 AM EST - 2 years ago

MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

Nov 14, 2022, 7:55 AM EST - 2 years ago

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

Oramed Reports Third Quarter 2022 Financial Results

Nov 10, 2022, 4:30 PM EST - 2 years ago

Oramed Reports Third Quarter 2022 Financial Results

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

Nov 9, 2022, 8:40 AM EST - 2 years ago

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

Oct 7, 2022, 8:40 AM EDT - 3 years ago

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Sep 21, 2022, 5:52 AM EDT - 3 years ago

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Sep 13, 2022, 8:40 AM EDT - 3 years ago

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 7:55 AM EDT - 3 years ago

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

Jul 26, 2022, 7:55 AM EDT - 3 years ago

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Jul 11, 2022, 7:55 AM EDT - 3 years ago

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

Jun 1, 2022, 7:55 AM EDT - 3 years ago

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

Oramed to Present at H.C. Wainwright Global Investment Conference

May 18, 2022, 7:55 AM EDT - 3 years ago

Oramed to Present at H.C. Wainwright Global Investment Conference

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

May 3, 2022, 8:10 AM EDT - 3 years ago

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

Oramed And Oral Insulin: Can This Small Company Really Do It?

Apr 14, 2022, 4:02 PM EDT - 3 years ago

Oramed And Oral Insulin: Can This Small Company Really Do It?

Oramed Appoints Yadin Rozov to its Board of Directors

Apr 4, 2022, 8:25 AM EDT - 3 years ago

Oramed Appoints Yadin Rozov to its Board of Directors

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

Mar 29, 2022, 8:25 AM EDT - 3 years ago

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

Mar 22, 2022, 8:25 AM EDT - 3 years ago

Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

Oramed to Present at Barclays Global Healthcare Conference

Mar 10, 2022, 8:25 AM EST - 3 years ago

Oramed to Present at Barclays Global Healthcare Conference

Oramed Issues Annual Message to Shareholders

Jan 12, 2022, 8:45 AM EST - 3 years ago

Oramed Issues Annual Message to Shareholders

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

Jan 5, 2022, 7:30 AM EST - 3 years ago

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

Dec 29, 2021, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh

Dec 29, 2021, 6:14 AM EST - 3 years ago

Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Dec 29, 2021, 6:00 AM EST - 3 years ago

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

Dec 14, 2021, 8:00 AM EST - 3 years ago

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

Oramed Pharmaceuticals Appoints Chief Legal Officer

Dec 8, 2021, 7:30 AM EST - 3 years ago

Oramed Pharmaceuticals Appoints Chief Legal Officer

Oramed to Join MSCI USA Small Cap Index

Nov 24, 2021, 8:40 AM EST - 4 years ago

Oramed to Join MSCI USA Small Cap Index

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

Nov 23, 2021, 8:25 AM EST - 4 years ago

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

Nov 18, 2021, 9:15 AM EST - 4 years ago

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

Nov 18, 2021, 7:40 AM EST - 4 years ago

Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

Oramed to Present at H.C. Wainwright 7th Annual Israel Conference

Nov 11, 2021, 9:25 AM EST - 4 years ago

Oramed to Present at H.C. Wainwright 7th Annual Israel Conference

Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Nov 8, 2021, 8:10 AM EST - 4 years ago

Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Nov 3, 2021, 11:59 AM EDT - 4 years ago

Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

WallStWireAds
WallStWireAds Aug. 4 at 12:34 AM
$ORMP The Next $1B Radiotherapy Bet? Why Alpha Tau Medical May Be One Breakthrough Away https://thefinanceherald.com/the-next-1b-radiotherapy-bet-why-alpha-tau-medical-may-be-one-breakthrough-away/
0 · Reply
ZacksSCR
ZacksSCR Jul. 28 at 9:09 PM
With Substantial Liquidity, $ORMP Has Generated Gains & Income From Investment Portfolio https://buff.ly/21CyOnj
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 25 at 12:28 AM
$ORMP Great piece that accurately captures ORMP's current position. So if you want to refresh your understanding of ORMP or learn about ORMP for the first time, this is essential reading. https://beyondspx.com/article/oramed-pharmaceuticals-oral-delivery-ambitions-face-pivotal-juncture-amidst-strategic-diversification-nasdaq-ormp
0 · Reply
kshonstocks
kshonstocks Jul. 23 at 6:39 PM
$ORMP alert hits some volume coming in
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 23 at 3:49 PM
$ORMP Very bullish. Load up early PT $3.5
0 · Reply
amitzak
amitzak Jul. 18 at 4:50 PM
$ORMP I'm in because: 1. Healthy cash status 2. started also investing in real estate lately 3. the company announced a one-year extension, allowing it to repurchase up to $20 million in value of its common stock, with the program now expiring in June 2026. As of May 2025, Oramed had repurchased approximately $2.5 million worth of shares under this program. 4. the price is near long term support levels.
0 · Reply
positiveguy
positiveguy Jul. 2 at 9:28 PM
$ORMP Trust me do not buy this stock. it is run by incompetent people and liars. the Ceo knows zero about managing a business. He pumped his bullshit drug for 20 years and has nothing to show for it except all the money he pilfered from the company. Look at how much he pays himself and his 90 year old mother and you will throw up. Shocked the SEC has not investigated this scam.
4 · Reply
Newyork_
Newyork_ Jul. 2 at 6:08 PM
$ORMP how are they still going
0 · Reply
CallMeMyBeer
CallMeMyBeer Jun. 27 at 9:15 PM
$ORMP its been years since their phase 3 failure and still no signs of anything working.
0 · Reply
PSDL75
PSDL75 Jun. 20 at 11:17 AM
$ORMP Quick glance at their pipeline, spend and cash - they seem in a decent sport, but not sure what amount of potential they actually have. The oral drug delivery companies appear to not be going anywhere. Though they have a cash runway...but the concerning part is all the financial finagling.. just going to watch this one.
1 · Reply
Itinerant
Itinerant Jun. 5 at 6:23 PM
$ORMP It appears that the company stopped buying their own shares today.
1 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 1 at 7:29 AM
$ORMP Watchlist for monday. PT 3+
0 · Reply
nickbs
nickbs May. 31 at 12:42 AM
$ORMP $18.62 according to report below.
0 · Reply
Jusbemoney
Jusbemoney May. 30 at 6:41 PM
$ORMP 5
0 · Reply
Itinerant
Itinerant May. 30 at 5:01 PM
$ORMP What a crap company. .... managed by a bunch of Jewish racist fanatics.
0 · Reply
Itinerant
Itinerant May. 30 at 3:01 PM
$ORMP I think that the company is the main buyer of the shares, and a few suckers reading this vacuous pump piece.
0 · Reply
BioTechHealthX
BioTechHealthX May. 30 at 11:40 AM
$ORMP Oramed is expanding pipeline includes oral GLP-1 analogs & treatments for NASH, signaling long-term growth potential. https://biotechhealthx.com/biotech-news/oramed-ormp-eyes-comeback-with-oral-glp-1-and-nash-pipeline-expansion/
2 · Reply
micheln1
micheln1 May. 20 at 12:15 PM
$ORMP how is this still a stock and is worth 2$ ???
1 · Reply
Itinerant
Itinerant May. 18 at 12:05 PM
$ORMP The company's 10Q report on the stall of the Chinese JV is quite negative. However, I point out that the Chinese/US issue will likely continue to thaw as Trump withdraws his idiotic and stupid posture. So, we can hope that the Chinese partner may find a way through the current obstacles and move the JV forward. I hope so because I think that the JV is an excellent strategic move, and the Chinese regulator's approval is very likely close at hand.
0 · Reply
Itinerant
Itinerant May. 16 at 8:39 AM
$ORMP The company 10Q finally reports that the Chinese JV closing is postponed due to issues in China deriving from the current geopolitical issues with the US. This is disappointing and casts some doubt on the credibility, in my opinion, of the Chinese partner.
0 · Reply
Armonica423
Armonica423 May. 11 at 12:18 AM
$ORMP Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
CallMeMyBeer
CallMeMyBeer May. 8 at 12:38 AM
$ORMP is Ben Shapiro still pumping this garbage? 🤣🤣🤣
1 · Reply